1. Home
  2. KALV vs EVER Comparison

KALV vs EVER Comparison

Compare KALV & EVER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KALV
  • EVER
  • Stock Information
  • Founded
  • KALV N/A
  • EVER 2008
  • Country
  • KALV United States
  • EVER United States
  • Employees
  • KALV N/A
  • EVER N/A
  • Industry
  • KALV Biotechnology: Pharmaceutical Preparations
  • EVER Computer Software: Programming Data Processing
  • Sector
  • KALV Health Care
  • EVER Technology
  • Exchange
  • KALV Nasdaq
  • EVER Nasdaq
  • Market Cap
  • KALV 796.4M
  • EVER 929.6M
  • IPO Year
  • KALV N/A
  • EVER 2018
  • Fundamental
  • Price
  • KALV $10.95
  • EVER $22.32
  • Analyst Decision
  • KALV Strong Buy
  • EVER Strong Buy
  • Analyst Count
  • KALV 8
  • EVER 5
  • Target Price
  • KALV $26.43
  • EVER $31.40
  • AVG Volume (30 Days)
  • KALV 1.5M
  • EVER 417.2K
  • Earning Date
  • KALV 09-11-2025
  • EVER 11-03-2025
  • Dividend Yield
  • KALV N/A
  • EVER N/A
  • EPS Growth
  • KALV N/A
  • EVER N/A
  • EPS
  • KALV N/A
  • EVER 1.24
  • Revenue
  • KALV $1,426,000.00
  • EVER $615,246,000.00
  • Revenue This Year
  • KALV N/A
  • EVER $32.27
  • Revenue Next Year
  • KALV $213.43
  • EVER $11.05
  • P/E Ratio
  • KALV N/A
  • EVER $17.97
  • Revenue Growth
  • KALV N/A
  • EVER 92.92
  • 52 Week Low
  • KALV $7.30
  • EVER $16.63
  • 52 Week High
  • KALV $17.28
  • EVER $30.03
  • Technical
  • Relative Strength Index (RSI)
  • KALV 27.85
  • EVER 38.11
  • Support Level
  • KALV $11.93
  • EVER $21.79
  • Resistance Level
  • KALV $12.43
  • EVER $23.92
  • Average True Range (ATR)
  • KALV 0.60
  • EVER 0.75
  • MACD
  • KALV -0.22
  • EVER -0.22
  • Stochastic Oscillator
  • KALV 6.17
  • EVER 14.17

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

About EVER EverQuote Inc.

EverQuote Inc is engaged in the business activity of offering an online marketplace for insurance shopping, connecting consumers with insurance provider customers, which includes both carriers and agents. The online marketplace offers consumers to find relevant insurance quotes based on car insurance, home insurance, and life insurance. The platform of the company is driven by data science. The firm's data and technology platform match and connects consumers seeking to purchase insurance with relevant options from its broad direct network of insurance providers. It derives a majority of revenue from Direct channels.

Share on Social Networks: